Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application

T cell receptor-engineered T (TCR-T) cells targeting neoantigens present potential immunotherapy for solid tumors. With the continuous optimization of the entire production procedures, the manufacturing process of TCR-T cells is becoming more efficient and productive. However, clinical-scale manufacturing of TCR-T cells still encounters tremendous challenges. Here, we summarize the latest progress of neoantigen-targeted TCR-T cell therapy and focus on the technical difficulties in preparing personalized neoantigen-targeted TCR-T cells and the challenges in clinical applications. Possible approaches for improving TCR-T cell therapy are discussed as well in this review.

Automated summary

TCR-T cell therapy targeting neoantigens shows promise for solid tumor immunotherapy. Despite the increasing efficiency and productivity in manufacturing TCR-T cells, clinical-scale production still faces significant challenges. This review summarizes the latest progress in neoantigen-targeted TCR-T cell therapy and discusses the technical difficulties in personalized preparation and the challenges in clinical applications.